An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP).

[1]  A. Cardona,et al.  Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non–Small Cell Lung Cancer , 2017, American journal of clinical oncology.

[2]  R. Rosell,et al.  O.01: Acquired Resistance to EGFR-TKIs in EGFR-Mutant Lung Adenocarcinoma Among Hispanics (RBIOP-CLICaP). , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  S. Novello,et al.  PD1.05 (also presented as P1.49): The Genomics of Young Emergent Lung Cancer. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  K. Rau,et al.  Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors. , 2016, Lung cancer.

[5]  L. Enewold,et al.  Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States , 2016, PloS one.

[6]  A. Hidalgo-Miranda,et al.  Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure , 2016, Respiratory Research.

[7]  M. Su,et al.  The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors. , 2016, Lung cancer.

[8]  P. Jänne,et al.  Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.

[9]  O. Arrieta,et al.  Real-World Patient Characteristics, Treatment Patterns, and Survival among Locally-Advanced/Metastatic Alk+ Non-Small Cell Lung Cancer Patients in Latin America. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  O. Arrieta,et al.  Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox". , 2015, Lung cancer.

[11]  R. Hubbard,et al.  Non-small cell lung cancer in young adults: presentation and survival in the English National Lung Cancer Audit. , 2015, QJM : monthly journal of the Association of Physicians.

[12]  Xiaolong Fu,et al.  Clinical significance of age at diagnosis among young non-small cell lung cancer patients under 40 years old: a population-based study , 2015, Oncotarget.

[13]  Jianying Zhou,et al.  Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger , 2015, PloS one.

[14]  W. Olszewski,et al.  Epidermal Growth Factor Receptor Mutation-Positive Non–Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Y. Wu,et al.  Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  V. Baracos,et al.  Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer. , 2015, The oncologist.

[17]  H. Wakelee,et al.  ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. , 2015, Cancer epidemiology.

[18]  G. Giaccone,et al.  Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States , 2015, Front. Oncol..

[19]  Matthew Meyerson,et al.  Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP) , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  M. Ladanyi,et al.  Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Quan Zhang,et al.  Crizotinib versus platinum‐based double‐agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase‐positive lung adenocarcinoma , 2015, Thoracic cancer.

[22]  L. Spaggiari,et al.  Molecular features and clinical outcome of lung malignancies in very young people. , 2015, Future oncology.

[23]  B. Solomon,et al.  First-line crizotinib in ALK-positive lung cancer. , 2015, The New England journal of medicine.

[24]  R. Rosell,et al.  The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. , 2015, Lung cancer.

[25]  L. Sequist,et al.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.

[26]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[27]  D. Ettinger,et al.  Molecular alterations in non-small cell lung carcinomas of the young. , 2014, Human pathology.

[28]  K. Kelly,et al.  Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis. , 2014, Lung cancer.

[29]  Tae Min Kim,et al.  Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2014, Cancer research and treatment : official journal of Korean Cancer Association.

[30]  R. McCormack,et al.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study , 2013, British Journal of Cancer.

[31]  C. Liam,et al.  Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma in Malaysian Patients , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  Kazuhisa Takahashi,et al.  High prevalence of gene abnormalities in young patients with lung cancer. , 2013, Journal of thoracic disease.

[33]  Richard Sullivan,et al.  Planning cancer control in Latin America and the Caribbean. , 2013, The Lancet. Oncology.

[34]  B. Parasuraman,et al.  EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital , 2013, PloS one.

[35]  A. Cardona,et al.  Clinical and Pathological Characteristics, Outcome and Mutational Profiles Regarding Non–Small-Cell Lung Cancer Related to Wood-Smoke Exposure , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  J. Shih,et al.  Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors , 2012, BMC Cancer.

[37]  Masahiro Fukuoka,et al.  Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Hyojin Kim,et al.  Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  G. Bepler,et al.  Frequency and Type of Epidermal Growth Factor Receptor Mutations in African Americans with Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[40]  A. Yoshizawa,et al.  Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene , 2010, Annals of Surgical Oncology.

[41]  J. Subramanian,et al.  Distinctive Characteristics of Non-small Cell Lung Cancer (NSCLC) in the Young: A Surveillance, Epidemiology, and End Results (SEER) Analysis , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[42]  L. Paz-Ares,et al.  Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.

[43]  F. Cappuzzo,et al.  Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[45]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[46]  Y. Ichinose,et al.  Lung cancer in patients younger than 40 years of age , 2001, Journal of surgical oncology.

[47]  D. Sugarbaker,et al.  Lung cancer in patients under age 40. , 2001, Lung cancer.

[48]  C. Liam,et al.  Lung cancer in patients younger than 40 years in a multiracial Asian country , 2000, Respirology.

[49]  S. Ramalingam,et al.  Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Rubin,et al.  Lung cancer in young adults. , 1992, Chest.

[51]  S. Jubelirer,et al.  Lung cancer in patients younger than 40 years of age , 1991, Cancer.

[52]  I. Wistuba,et al.  Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America , 2017, Clinical lung cancer.